Treatment of bone loss in osteopenic patients with Crohn's disease: a double-blind, randomised trial of oral risedronate 35 mg once weekly or placebo, concomitant with calcium and vitamin D supplementation

Conclusions A 24-month treatment course with risedronate 35 mg once weekly, concomitant with calcium and vitamin D supplementation, in osteopenic Crohn's disease patients improved bone density at lumbar spine. NTR 163 Dutch Trial Register.

http://gut.bmj.com/cgi/content/short/63/9/1424?rss=1

Source: Gut - August 3, 2014 Category: Gastroenterology Authors: van Bodegraven, A. A., Bravenboer, N., Witte, B. I., Dijkstra, G., van der Woude, C. J., Stokkers, P. C. M., Russel, M. G., Oldenburg, B., Pierik, M., Roos, J. C., van Hogezand, R. A., Dik, V. K., Oostlander, A. E., Netelenbos, J. C., van de Langerijt, L. Tags: Crohn's disease Inflammatory bowel disease Source Type: research